- 4-Week # shares sold: 228,235
- 12-Week # shares sold: 232,235
- 24-Week # shares sold: 235,235
Impax (IPXL) reported lower-than-anticipated earnings and revenue for the 2016 second quarter and a downbeat forecast before Tuesday's market open.
The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.
Australia's Mayne will shell out $652 million for a basket of generics products from Teva as the latter works to complete its pending Allergan generics purchase.
Trade-Ideas LLC identified Impax Laboratories (IPXL) as a "dead cat bounce" (down big yesterday but up big today) candidate